JESSICA COLEMAN: Open Payments
NPI 1992218986 · BRUNSWICK, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,315 in 73 payments from 19 companies in 2025. Trend: 2023 $1,564 · 2024 $1,609 · 2025 $1,315
Food & beverage: $1,315
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $259 |
| ABBVIE INC. | 16 | $252 |
| Alkermes, Inc. | 7 | $173 |
| Lilly USA, LLC | 6 | $104 |
| Axsome Therapeutics, Inc. | 4 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Novo Nordisk Inc | 3 | $63 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| Bausch Health US, LLC | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
Products named: TRINTELLIX, VRAYLAR, ARISTADA, Auvelity, MOUNJARO, REXULTI, SPRAVATO, APLENZIN.
Industry payments across GA — which companies pay providers there.
